On March 17, 2026 Prescient Therapeutics Ltd (ASX:PTX) is advancing enrolment in its Phase 2 clinical trial for lead asset PTX-100, with new research highlighting steady progress across trial execution, regulatory milestones and funding — while pointing to valuation upside from current levels.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A new report from Pitt Street Research outlines growing momentum behind PTX-100, a first-in-class oncology drug targeting relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare and difficult-to-treat cancer where treatment options remain limited.
5
The therapy works by inhibiting GGTase-1, a pathway involved in cancer cell signalling and survival, offering a differentiated approach compared with existing treatment classes.
Phase 2 footprint expands
The Pitt Street report noted that Prescient’s Phase 2 trial continues to scale, with eight of a planned 16 global sites now established and enrolling patients.
The study is structured in two stages, beginning with dose optimisation before expanding into a broader efficacy and safety phase. Key endpoints include objective response rate, along with progression-free survival and duration of response.
Clinical sites across the US and Australia are already active, with European expansion underway — a key step expected to support recruitment in a relatively small and specialised patient population.
The report highlights European site activation as a critical near-term driver, particularly as new investigators come on board to help lift enrolment rates and accelerate data flow through 2026.
Early data supports differentiated approach
While Phase 2 remains in its early stages, the investment case continues to be anchored by encouraging Phase 1 results.
PTX-100 delivered a 43% overall response rate and a 100% clinical benefit rate in earlier studies, alongside a favourable safety profile with no serious adverse events attributed to the drug.
That combination is particularly relevant in CTCL, where existing therapies often struggle to deliver durable responses without significant side effects.
The research note argues the drug’s unique mechanism and early data position it as a potentially differentiated option in this setting, while also opening the door to broader applications across other cancers.
"PTX-100’s status as the only GGTase-1 inhibitor in clinical development anywhere in the world, and one with far more promising results than any TCL drugs on the market, gives it a uniqueness that is attractive to potential pharmaceutical partners."
Regulatory progress and funding support
Recent regulatory milestones are also strengthening the commercial outlook.
PTX-100 has secured orphan drug designation in both the US and Europe for CTCL, providing incentives such as market exclusivity, regulatory support and reduced fees — factors that can help streamline development and improve long-term economics.
Prescient has also reinforced its balance sheet, raising $9.8 million in capital and receiving a $4.3 million R&D tax incentive refund, extending its cash runway into 2027.
This funding position supports continued clinical progress while allowing the company to explore potential partnering opportunities.
Partnerships and broader pipeline optionality
Beyond PTX-100, the report points to additional upside from Prescient’s pipeline, including its OmniCAR and CellPryme platforms.
These technologies are designed to enhance cell therapy approaches such as CAR-T, addressing limitations around durability, efficacy and control. The company is currently seeking collaborations to advance these programmes, creating additional pathways for value creation.
However, the most significant near-term catalyst remains PTX-100, particularly as Phase 2 data begins to build.
"A pharma partnership — whether in the form of a co-development agreement, regional licensing deal, or broader collaboration — would be a transformative catalyst for Prescient’s valuation and share price."
The report notes that meaningful Phase 2 data will likely be required before major deals are struck, although early engagement with potential partners is already under way.
Valuation highlights upside, with risks in focus
Pitt Street Research has reiterated its valuation range of $0.11 to $0.16 per share, based on a risk-adjusted net present value model incorporating PTX-100, CellPryme and the company’s cash position.
PTX-100 accounts for the majority of that valuation, reflecting its position as the company’s lead and most advanced asset.
At current levels around $0.06 per share, the report implies material upside, contingent on continued clinical progress and successful execution of the Phase 2 programme.
As with all clinical-stage biotech companies, risks remain. Pitt Street notes that for Prescient, these include potential delays in patient enrolment, regulatory uncertainty and the possibility of future capital requirements, alongside the inherent variability of clinical outcomes as trials expand.
According to the researchers, with Prescient’s differentiated mechanism, supportive early data and expanding trial infrastructure, the company is entering a critical period where execution — particularly around enrolment and data delivery — will be key to unlocking that potential.